Manufacturer or GPO Program year 2024 Source: CMS Open Payments

4DMedical USA Inc

CA, United States

CMS manufacturer 100001396986

Open in the dashboard

General payments

$448,657

107 payments

Research payments

$1,236,070

5 payments

Ownership & investment interest

$0

None reported

Through program year 2024, 4DMedical USA Inc reported paying $448,657 in general payments and $1,236,070 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2024 General $233,460 64
2024 Research $86,148 1
2023 General $215,198 43
2023 Research $1,149,923 4

Breakdown

Top recipients General payments · program year 2024
  1. David Shulkin Internal Medicine · Morristown, NJ $121,710 16 payments
  2. Robert Figlin Hematology & Oncology · Duarte, CA $62,397 13 payments
  3. Geraldine McGinty Diagnostic Radiology · New York, NY $48,359 14 payments
  4. Douglas Hogarth Pulmonary Disease · Chicago, IL $115 3 payments
  5. Joseph Cicenia Pulmonary Disease · Cleveland, OH $96 3 payments
  6. Michael Morris Pulmonary Disease · Fort Sam Houston, TX $94 1 payment
  7. Christoph Wald Diagnostic Radiology · Rochester, MN $86 1 payment
  8. Robert Miller Pulmonary Disease · Nashville, TN $71 1 payment
  9. Myron Kung Pulmonary Disease · North Las Vegas, NV $70 1 payment
  10. Raymond Casciari Pulmonary Disease · Orange, CA $68 1 payment
Top research recipients Research payments · program year 2024
  1. Mount Sinai Hospital Teaching hospital · NY $86,148 1 payment
Products the payments named General payments · program year 2024
  1. CT Lvas Lung imaging software and device $233,460 100% · 20 recipients

Each share is of this company’s general payments naming a product in 2024. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2024
  1. Internal Medicine $121,710 52% · 1 practitioner
  2. Hematology & Oncology Internal Medicine $62,397 27% · 1 practitioner
  3. Diagnostic Radiology Radiology $48,597 21% · 5 practitioners
  4. Pulmonary Disease Internal Medicine $756 <1% · 13 practitioners

Each share is of this company’s general payments to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2024
  1. New Jersey $121,710 52% · 1 recipient
  2. California $62,548 27% · 4 recipients
  3. New York $48,359 21% · 1 recipient
  4. Tennessee $155 <1% · 3 recipients
  5. Massachusetts $137 <1% · 2 recipients

The top 5 of 13 states; each share is of this company’s general payments in 2024 where a state was reported.

The top 25 states, free in the app

What the payments were for General payments · program years 2023–2024
  1. Consulting Fee $399,051 67 payments
  2. Travel and Lodging $41,772 7 payments
  3. Entertainment $5,813 4 payments
  4. Food and Beverage $2,022 29 payments
107 general · 5 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record